ReViral Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 22

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $525M

ReViral General Information

Description

Developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drug is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe diseases including neonates, enabling patients to be treated who are infected with the respiratory syncopal virus (RSV) by developing novel compounds.

Contact Information

Formerly Known As
Re:viral Limited
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Stevenage Bioscience Catalyst
  • Gunnels Wood Road, Hertfordshire
  • Stevenage SG1 2FX
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • Stevenage Bioscience Catalyst
  • Gunnels Wood Road, Hertfordshire
  • Stevenage SG1 2FX
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ReViral Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 06-Apr-2022 $525M Completed Clinical Trials - Phase 2
5. Later Stage VC (Series C) 25-Aug-2020 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series B) 01-Aug-2018 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 08-Sep-2015 Completed Pre-Clinical Trials
2. Angel (individual) 03-Dec-2014 $1.57M $1.83M Completed Pre-Clinical Trials
1. Angel (individual) 26-Feb-2013 $252K $252K Completed Startup
To view ReViral’s complete valuation and funding history, request access »

ReViral Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A
Series A
Ordinary 4,355 $0.013069 $6.53 $6.53 $6.53 2.17%
Ordinary 12,400 $0.013069
To view ReViral’s complete cap table history, request access »

ReViral Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-cla
Drug Discovery
Stevenage, United Kingdom
22 As of 2022

Tucson, AZ
 

Brighton, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ReViral Competitors (14)

One of ReViral’s 14 competitors is Aqualung Therapeutics, a Venture Capital-Backed company based in Tucson, AZ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aqualung Therapeutics Venture Capital-Backed Tucson, AZ
Enterprise Therapeutics Venture Capital-Backed Brighton, United Kingdom
Baliopharm Venture Capital-Backed Basel, Switzerland
Melinta Therapeutics Private Equity-Backed Parsippany, NJ
Cerecin Venture Capital-Backed Broomfield, CO
You’re viewing 5 of 14 competitors. Get the full list »

ReViral Patents

ReViral Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022180397-A1 Benzodiazepines for treating or preventing respiratory syncytial virus infection Inactive 24-Feb-2021
GB-202102602-D0 Pharmaceutical compounds Inactive 24-Feb-2021
US-20230270751-A1 Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection Active 07-Jul-2020
US-20230365585-A1 Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection Inactive 07-Jul-2020
WO-2022008911-A1 Benzodiazepine derivatives useful in treating a respiratory syncytial virus infection Inactive 07-Jul-2020 C07D498/04
To view ReViral’s complete patent history, request access »

ReViral Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ReViral Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Andera Partners PE/Buyout Minority
Brace Pharma Capital Corporate Venture Capital Minority
Charoen Pokphand Group Corporation Minority
China Resources Capital Management Corporate Venture Capital Minority
Green Sands Equity Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

ReViral FAQs

  • When was ReViral founded?

    ReViral was founded in 2011.

  • Where is ReViral headquartered?

    ReViral is headquartered in Stevenage, United Kingdom.

  • What is the size of ReViral?

    ReViral has 22 total employees.

  • What industry is ReViral in?

    ReViral’s primary industry is Drug Discovery.

  • Is ReViral a private or public company?

    ReViral is a Private company.

  • What is the current valuation of ReViral?

    The current valuation of ReViral is .

  • What is ReViral’s current revenue?

    The current revenue for ReViral is .

  • How much funding has ReViral raised over time?

    ReViral has raised $126M.

  • Who are ReViral’s investors?

    Andera Partners, Brace Pharma Capital, Charoen Pokphand Group, China Resources Capital Management, and Green Sands Equity are 5 of 10 investors who have invested in ReViral.

  • Who are ReViral’s competitors?

    Aqualung Therapeutics, Enterprise Therapeutics, Baliopharm, Melinta Therapeutics, and Cerecin are some of the 14 competitors of ReViral.

  • When was ReViral acquired?

    ReViral was acquired on 06-Apr-2022.

  • Who acquired ReViral?

    ReViral was acquired by Pfizer.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process